The ABHD14B Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population carrying targeted disruption of the ABHD14B gene. This product constitutes a loss-of-function model for investigating ABHD14B, an alpha/beta hydrolase domain-containing protein with putative lysine deacetylase activity. The polyclonal knockout approach provides a heterogeneous pool of edited cells, enabling robust functional genomics studies and bulk assays without the limitations of single-cell clones. Researchers can utilize this system to examine ABHD14B-dependent molecular mechanisms in a controlled genetic context.
The host HeLa cell line is a human cervical adenocarcinoma epithelial model, positive for HPV18, with p53 and retinoblastoma protein (Rb) inactivated by the viral E6 and E7 oncoproteins, respectively. This well-characterized cancer cell line is widely employed in studies of cervical cancer biology, signal transduction, and gene function. Its defined genetic background and reproducible growth characteristics make it an ideal platform for dissecting pathways involved in proliferation, apoptosis, and transformation.
ABHD14B is a member of the alpha/beta hydrolase superfamily and encodes a putative lysine deacetylase that binds directly to calmodulin (CALM1/CALM2/CALM3). This interaction positions ABHD14B at the interface of calcium signaling and protein deacetylation, presumably functioning downstream of calcium/calmodulin activation. The enzyme is believed to target specific deacetylated protein substrates, potentially histones or non-histone proteins, thereby modulating acetylation-dependent processes such as gene expression and protein stability. The calmodulin-ABHD14B-substrate axis represents a putative mechanism linking calcium fluxes to the cellular acetylome.
In the HeLa cervical cancer context, ABHD14B knockout permits functional dissection of its role in acetylation-mediated regulation of cell proliferation and apoptosis. With p53 and Rb pathways already disrupted, this model is valuable for evaluating whether ABHD14B exerts tumor-suppressive or oncogenic functions. It enables identification of ABHD14B-dependent acetylation changes on key regulatory proteins and assessment of their impact on cellular responses to calcium. Moreover, the system can be used to test sensitivity to deacetylase inhibitors in a cancer-relevant background.
Applications include functional characterization of ABHD14B deacetylase activity, investigation of calcium-dependent signaling cascades, and analysis of protein acetylation dynamics. Typical assays involve Western blotting for acetylated proteins, co-immunoprecipitation to confirm calmodulin binding, cell viability and apoptosis assays, calcium imaging, and deacetylase enzymatic measurements. The polyclonal knockout pool is also suited for CRISPR-based screens and downstream target validation. For further technical details, please contact Ascent Research.
